Open AccessThe metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells
Author(s) -
Fangyong Dong,
Michael Eibach,
Jörg W. Bartsch,
Amalia M. Dolga,
Uwe Schlomann,
Catharina Conrad,
Susanne Schieber,
Oliver Schilling,
Martin L. Biniossek,
Carsten Culmsee,
Herwig Strik,
Garrit Koller,
Barbara Carl,
Christopher Nimsky
Publication year - 2015
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/nov042
Subject(s) - metalloproteinase , temozolomide , cancer research , disintegrin , matrix metalloproteinase , chemistry , tissue inhibitor of metalloproteinase , pi3k/akt/mtor pathway , cell culture , biology , signal transduction , glioma , biochemistry , genetics
Despite multimodal treatment, glioblastoma (GBM) therapy with temozolomide (TMZ) remains inefficient due to chemoresistance. Matrix metalloproteinase (MMP) and a disintegrin and metalloprotease (ADAM), increased in GBM, could contribute to chemoresistance and TMZ-induced recurrence of glioblastoma.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom